Skip to main content
. 2022 Nov 2;4(6):fcac282. doi: 10.1093/braincomms/fcac282

Table 1.

Participant demographics. Mean values (SDs) are shown

Non-Progressors Progressors Statistical Significance (P-value)
Number of subjects 226 48
Age at baseline 67.42 (SD 6.46) 69.33 (SD 8.20) 0.0788
Gender (male/female) 90/136 18/30 0.7649
Education 15.85 (SD 2.50) 15.13 (SD 2.48) 0.0703
CDR slope 0 0.0607(SD 0.082) 8.45*10−24
% Baseline CDR = 0 94% 90% 0.3388
MMSE Slope 0 −0.345 (SD 0.580) 7.5*10−10
Length of time in study 8.16 (SD 3.76) 10.42 (SD 5.35) 5.7*10−4
APOE status (e2*/e3e3/e3e4 or e4e4) 39/126/61 8/22/18 0.4819
Race (Caucasian/African American/Asian) 202/23/1 45/3/0 0.6251
Ethnicity (Non-Hispanic/Hispanic) 225/1 48/0 0.6443
Amyloid-β+ baseline 46 (20%) 25 (53%) 1.0*10−5
Amyloid-β+ last follow-up 73 (32%) 27 (56%) 0.002
Number of amyloid follow-up visits 2.65 (SD 0.98) 2.77 (SD 0.99) 0.4094
Number of MRI follow-up visits 3.15 (SD 1.01) 3.14 (SD 1.05) 0.9242

CDR, clinical dementia rating; MMSE, mini-mental state examination. Average age, education, CDR and MMSE slopes (per year) and length of time in study are shown along with SD. For categorical comparisons, we used χ2 test, while for continuous variables, we used a one-way analysis of variance.